

MAY 14, 2020 ONLINE & BY PHONE







49 MALE NOBEL LAUREATES. O FEMALE. LET'S CHANGE THAT.



Creating a cancer-free world. One person, one discovery at a time.



The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Outline

- Personal Path to Cancer Research
- The James Cancer Hospital at Ohio State University
- Department of Radiation Oncology
- Translational Cancer Research Efforts
 - Precision Biomarkers
 - Proton Therapy
 - FLASH Radiation Therapy
- Cancer Research Funding





Personal Path to Cancer Research



Jessica Fleming, PhD Radiobiologist








The Ohio State University

- One of the <u>largest</u> universities in USA
- 62K students; 40K faculty & staff
- 14 colleges
- Most comprehensive health sciences campus in USA

Comprehensive Cancer Center

- NCI "Comprehensive" status since 1976
- 270+ member investigators
 - OSU, Nationwide Children's & Cincinnati Children's
- Five (5) scientific programs
- Twenty (20) Shared Resources
- The James Cancer Hospital





The James Cancer Hospital and Solove Research Institute

21st century hospital

- 3rd largest cancer hospital in the US
- Sub-specialized, multidisciplinary clinical care model
- 21 floors
- 14 Cancer-Related Operating Rooms

James Interactive Cancer Research Programs:

- Cancer Control
- Leukemia
- Molecular Biology and Cancer Genetics
- Molecular Carcinogenesis and Chemoprevention
- Translational Therapeutics







The Ohio State University

Department of Radiation Oncology





8

James Radiation Oncology Team





World-Class Radiation Oncology



World-Class Radiation Oncology



Translational Cancer Research

Primary Goal:


Development of novel, more effective <u>personalized care</u> strategies for cancer patients.

Key Strategies:

- Identification of molecular biomarkers in cancer patients that can aid in diagnosis, prognosis, and treatment planning.
- Identification of pathways driving cancer progression and developing personalized targeted treatment options that increase survival and quality of life.

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Personalized Care Strategies





Cancer Types of Interest


- Brain (Primary and Metastatic)
- Prostate
- Head & Neck
- Cervical
- Gastrointestinal
- Pediatric
- Lung
- Kidney
- Bladder
- Sarcoma
- Melanoma





Biomarker Identification Pipeline

Biomarker: A biological molecule found in blood or tissues that is a sign of a normal or abnormal process, or of a condition or <u>disease</u>.



Radiation Oncology Key Publications

| N 19(5) Research Amole JAMA ON Research AMA ON Research AMA ON Research AMA ON Research AMA ON Person https://doi.0 ACOI With ! Frica Havin Antiony M Aline P. Bec Antiony M Aline P. Bec An An Deficition J. Esse Denise Fablian Jean-Paul Ball Frica H. Bell, Glenn J. Lesse Denise Fablian Jean-Paul Ball Frica H. Bell, Glenn J. Lesse Denise Fablian Jean-Paul Ball Frica H. Bell, Glenn J. Lesse Denise Fablian Heidi J. Gray,1 Heidi J | d temozolomide or anaplastic |
|--|---------------------------------|
|--|---------------------------------|

Susan Chang, Peixin Zhang, J. Gregory Cairncross, Mark R. Gilbert, Jean-Paul Bahary, Carol A. Dolinskas, Arnab Chakravarti, Kenneth D. Aldape, Erica H. Bell, David Schiff, Kurt Jaeckle, Paul D. Brown, Geoffrey R. Barger, Maria Werner-Wasik, Helen Shih, David Brachman, Marta Penas-Prado, H. Ian Robins, Karl Belanger, Christopher Schultz, Grant Hunter, and Minesh Mehta






The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

Overall Survival among Patients with IDH1 R132H Mutation



The James

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Ohio State Partnered with Nationwide Children's **Hospital To Bring Proton Therapy To Central Ohio!**

Health Care

Ohio State, Nationwide Children's to team up on \$100 mill proton therapy cancer center





November 20, 2018

Ad closed

Stop se

Why th

Home

Region's first proton therapy facility to treat cancer patients

THE OHIO STATE UNIVERSITY

The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are collaborating with Nationwide Children's Hospital to bring the first proton therapy treatment facility to central Ohio. This will offer state-of-the-art radiation oncology treatment for adult and pediatric cancer patients in one place.

The proton center will be located at the new 340,000 square-foot outpatient facility planned for Ohio State's west campus. The proton therapy portion is expected to utilize 55,000 square feet and cost approximately \$100 million. Nationwide Children's has committed to up to 50 percent of the expected proton center project cost.

"This is a significant advancement for our patients and their families," said Ohio State President Michael V. Drake, "As part of our nationally renowned Wexner Medical Center, comprehensive cancer center and health sciences campus, this facility will spark leading-edge research, inspire new academic partnerships and drive innovative solutions to combat this ubiquitous and devastating disease"

Ohio State News

Share

Region's first proton therapy facility to treat cancer patients




Get the latest Ohio State News


Email address

Send



Treatment Benefits of Proton Therapy






- Targets tumors and cancer cells with precision
- Reduces short- and long-term side effects on surrounding healthy tissues /organs
- Can be used to treat recurrent tumors and patients previously treated with radiation
- Improves quality of life during and after treatment
- Increases the long-term survival rates



OSU Will Be One Of The <u>First</u> Centers Capable Of Delivering Proton And Electron <u>FLASH</u> Radiotherapy



FlashForward[™] + RapidScan will Boost Dose Rates



3 VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

varian




FLASH Radiotherapy

Ultrahigh dose-rate radiation delivered in a <u>very short period of time that produces a</u> damaging effect in tumor tissue while sparing surrounding normal tissues.



Dose distribution in mini pig








²¹ Vozenin MC et al. (2019) CCR. 25: 35-42

A Single FLASH Radiotherapy Demonstrates Excellent Tumor Control In Small Animals

Dose distribution in cat SCC patient



Before FLASH-RT



14 months post FLASH-RT





OSU Received IntraOp Mobetron Spring 2020 To Begin Pre-Clinical FLASH Electron Studies



Pre-clinical research studies:

Mice

Zebrafish

Vet School Clinical Trials





OSU FLASH Team



Arnab Chakravarti, MD Chair, Radiation Oncology



Dukagjin Blakaj, MD, PhD Radiation Oncologist

24



John Grecula, MD Radiation Oncologist



Nilendu Gupta, PhD Chief, Medical Physics



Ahmet Ayan, PhD Medical Physicist



Jessica Fleming, PhD Radiobiologist



Radiobiologist



Cecilia Cuitino, DVM, PhD Veterinary Pathologist





Research Funding

- OSUMC received \$100 million dollars from the Health and Human Services Grant
- OSUMC also received a 2nd very generous donation of \$100 million dollars.
- OSU has received >\$25 million dollars in research funding for Federal/NIH-related projects and grants over the past five years.
- OSU is ranked 7th in NIH funding amongst Radiation Oncology.





RIDE AS ONE -> RAISE AS ONE



Main Takeaways

- Advancements in molecular techniques have launched the cancer field into the era of personalized medicine.
- Proton and FLASH radiotherapy have the potential to revolutionize the way we treat cancer patients!
- Work of American Cancer Society Cancer Action Network is critical to further advancements in cancer research!







Thank You!

To learn more about Ohio State's cancer program, please visit **cancer.osu.edu** or follow us in social media:

f > in **Q**⁺ **™ ∅ €**

And please visit the Department of Radiation Oncology at **radiationoncology.osu.edu**

Jessica.Fleming@osumc.edu





VIRTUAL E Cancer Action

CANCER ACTION DAY

#OHIOFIGHTSCANCER

Coach Chris Holtmann, The Ohio State University





National Cancer Information Center

American Cancer Society Cancer Action Network

Cancer Action Network™

> American Cancer Society® /



Judy's Story Road To Recovery

American Cancer Society®

VIRTUAL Province Action



#OHIOFIGHTSCANCER



Delmar's Story The Hope Lodge

American Cancer Society®

VIRTUAL American

CANCER ACTION DAY

#OHIOFIGHTSCANCER











IMPACT AND IMPORTANCE OF BIOMEDICAL RESEARCH FUNDING

Scott M Langevin, PhD, MHA, CT(ASCP) Associate Professor of Epidemiology Co-Director, Clinical & Translational Research Graduate Education Program Department of Environmental & Public Health Sciences University of Cincinnati College of Medicine

May 14, 2020





40

- PhD (Epidemiology) from University of Pittsburgh Graduate School of Public Health (2010)
- Postdoctoral Fellowship in Cancer Epidemiology and Environmental Pathology at Brown University (2010-2013)
- Faculty member with UC College of Medicine Department of Environmental & Public Health Sciences (2013-Present)
 - Currently tenured Associate Professor of Epidemiology

My Research...

Molecular Epidemiology / Pathobiology of Respiratory Tract Cancers

- Cancer epigenetics
- Biomarker discovery and development
- Etiology (cancer causes and risk factors)




ACS Grant Funding




- Received ACS Research Scholar (Jan 2019 2022)
 Head and neck cancers have among the highest recurrence rates of all cancers
 - \sim 50% will recur within 2-years of treatment
 - Earlier detection of recurrent cancer is associated with better outcomes
 - Applying our patented biomarker panel in oral rinse (mouthwash) for early detection of recurrence following oral cancer treatment


Need for Outside Support **43** 7×11=670 10 Donations 0




Success Rates for NIH & NCI Grant Applications



Increasing Age of NIH-Funded Principal Investigators



Source of New FDA-Approved Drugs



Source: Patridge et al. Drug Discov Today. 2015;20(10):1182-7.

Don't Forget About Us!...

48

 Institute for Health Metrics and Evaluation (IHME) predicts 137,184 COVID-19 deaths through Aug 2020
 American Cancer Society (ACS): 1,806,590 new cancer cases and 606,520 cancer deaths in US in 2020
 Siegel et al. CA Cancer J Clin. 2020;70(1):7-30

Underscores the critical importance of sustained funding for cancer research!

THANK YOU!

Email: langevst@uc.edu

ACS Research Program

Road to Recovery

Real Men Wear Pink

REAL

Lights of Hope

VIRTUAL Preventation



#OHIOFIGHTSCANCER





acscan.org

©2014 American Cancer Society Cancer Action Network, Inc. - No. 002542